Table 1 Clinical characteristics of patients
Characteristics | With baseline biopsy (n = 51) | With follow-up biopsy (n = 37) |
|---|---|---|
Age, years | ||
 Median (range) | 64 (46–76) | 64 (46–72) |
Sex | ||
 Male | 40 (78.4) | 31 (83.8) |
 Female | 11 (21.6) | 6 (16.2) |
Smoking | ||
 Never | 27 (52.9) | 18 (48.6) |
 Ever/current | 24 (47.1) | 19 (51.4) |
Histology | ||
 NOS | 7 (13.7) | 6 (16.2) |
 Adenocarcinoma | 27 (52.9) | 17 (45.9) |
 Squamous | 17 (33.3) | 14 (37.8) |
Stage | ||
 IIIB-IIIC | 13 (25.5) | 10 (27.0) |
 IV | 38 (74.5) | 27 (73.0) |
Tumor size | ||
 ≤ 5 cm | 36 (70.6) | 27 (73.0) |
 > 5 cm | 15 (29.4) | 10 (27.0) |
Number of metastatic organs | ||
 0–1 | 37 (72.5) | 27 (73.0) |
 ≥ 2 | 14 (27.5) | 10 (27.0) |
Metastasis sites | ||
 Lung | 26 (51.0) | 18 (48.6) |
 Brain | 4 (7.8) | 2 (5.4) |
 Bone | 8 (15.7) | 6 (16.2) |
 Liver | 2 (3.9) | 2 (5.4) |
 Adrenal | 2 (3.9) | 2 (5.4) |
 Lymph gland | 9 (17.6) | 6 (16.2) |
 Others | 0 (0) | 5 (13.5) |
PD-L1a | ||
 Positive | 12 (40.0) | 9 (39.1) |
 Negative | 18 (60.0) | 14 (60.9) |
 Unknown | 21 | 14 |
ICIs Lines | ||
 1 | 34 (66.7) | 26 (70.3) |
 ≥ 2 | 17 (33.3) | 11 (29.7) |
ICIs drug | ||
 Pembrolizumab | 18 (35.3) | 13 (35.1) |
 Camrelizumab | 11 (21.6) | 8 (21.6) |
 Sintinimab | 16 (31.4) | 11 (29.7) |
 Tislelizumab | 4 (7.8) | 4 (10.8) |
 Toripalimab | 2 (3.9) | 1 (2.7) |
Chemo-drugb | ||
 Pemetrexed | 15 (29.4) | 9 (24.3) |
 Gemcitabine | 11 (20.6) | 9 (24.3) |
 Paclitaxel | 19 (37.2) | 14 (37.8) |
 Docetaxel | 6 (11.8) | 5 (13.5) |